Back to Search
Start Over
Genomic and Epigenomic Integration Identifies a Prognostic Signature in Colon Cancer
- Source :
- Clinical Cancer Research, 17(6), 1535-1545. American Association for Cancer Research Inc.
- Publication Year :
- 2011
- Publisher :
- American Association for Cancer Research (AACR), 2011.
-
Abstract
- Purpose: The importance of genetic and epigenetic alterations maybe in their aggregate role in altering core pathways in tumorigenesis. Experimental Design: Merging genome-wide genomic and epigenomic alterations, we identify key genes and pathways altered in colorectal cancers (CRC). DNA methylation analysis was tested for predicting survival in CRC patients using Cox proportional hazard model. Results: We identified 29 low frequency-mutated genes that are also inactivated by epigenetic mechanisms in CRC. Pathway analysis showed the extracellular matrix (ECM) remodeling pathway is silenced in CRC. Six ECM pathway genes were tested for their prognostic potential in large CRC cohorts (n = 777). DNA methylation of IGFBP3 and EVL predicted for poor survival (IGFBP3: HR = 2.58, 95% CI: 1.37–4.87, P = 0.004; EVL: HR = 2.48, 95% CI: 1.07–5.74, P = 0.034) and simultaneous methylation of multiple genes predicted significantly worse survival (HR = 8.61, 95% CI: 2.16–34.36, P < 0.001 for methylation of IGFBP3, EVL, CD109, and FLNC). DNA methylation of IGFBP3 and EVL was validated as a prognostic marker in an independent contemporary-matched cohort (IGFBP3 HR = 2.06, 95% CI: 1.04–4.09, P = 0.038; EVL HR = 2.23, 95% CI: 1.00–5.0, P = 0.05) and EVL DNA methylation remained significant in a secondary historical validation cohort (HR = 1.41, 95% CI: 1.05–1.89, P = 0.022). Moreover, DNA methylation of selected ECM genes helps to stratify the high-risk stage 2 colon cancers patients who would benefit from adjuvant chemotherapy (HR: 5.85, 95% CI: 2.03–16.83, P = 0.001 for simultaneous methylation of IGFBP3, EVL, and CD109). Conclusions: CRC that have silenced genes in ECM pathway components show worse survival suggesting that our finding provides novel prognostic biomarkers for CRC and reflects the high importance of integrative analyses linking genetic and epigenetic abnormalities with pathway disruption in cancer. Clin Cancer Res; 17(6); 1535–45. ©2011 AACR.
- Subjects :
- Epigenomics
Male
Cancer Research
Colorectal cancer
Biology
Medical Oncology
Bioinformatics
medicine.disease_cause
Article
Epigenesis, Genetic
Cohort Studies
Recurrence
Cell Line, Tumor
Biomarkers, Tumor
medicine
Humans
Epigenetics
FLNC
Aged
Proportional Hazards Models
Gene Expression Profiling
Cancer
Genomics
Methylation
DNA Methylation
Middle Aged
Prognosis
medicine.disease
Extracellular Matrix
Treatment Outcome
Oncology
Chemotherapy, Adjuvant
Colonic Neoplasms
DNA methylation
Cancer research
CpG Islands
Female
Carcinogenesis
Subjects
Details
- ISSN :
- 15573265 and 10780432
- Volume :
- 17
- Database :
- OpenAIRE
- Journal :
- Clinical Cancer Research
- Accession number :
- edsair.doi.dedup.....7c7a3a409f4a4fbdf4b14e1d0bbf3435
- Full Text :
- https://doi.org/10.1158/1078-0432.ccr-10-2509